Achieving universal health coverage and health for all is a shared global vision, but climate, economy, infectious diseases and other factors affect human health. Among them, infectious diseases should not be underestimated. WHO Director-General Tedros Adhanom Ghebreyesus has said, "This shared responsibility must be centred around the One Health approach to strengthen the world's defenses against global and endemic pandemics such as the pandemic."
Over the past few decades, pandemics of infectious diseases such as hepatitis, tuberculosis, malaria and influenza have all made the implementation of the One Health strategy and the journey to "Health for All" in every country urgent. In the past, China was also plagued by infectious diseases, and the road to a healthy China is also walking on thin ice.
In the early days of reform and opening up, China was plagued by hepatitis B virus, and its incidence and mortality increased year by year, and the infection rate was as high as about 10%. At this time, the development of high-quality and inexpensive domestic hepatitis B detection reagents has become the first important task to block hepatitis B disease. INTCO is the first domestic manufacturer to launch hepatitis B enzyme-linked immunoassay dry coating reagent, which helps greatly improve the detection efficiency.
Since then, INTCO has launched a variety of diagnostic reagents: in 1993, it launched the first batch of hepatitis C diagnostic reagents in ChinaIn 1994, the "Trust Method" syphilis diagnostic kit with leading technology was launchedIn 1995, the first batch of AIDS diagnostic reagents in China was successfully developed and marketed. In the enzyme-linked immunoassay technology platform, INTCO has established its industry-leading position in the field of infectious diseases and venereal disease detection with high-quality products.
At the end of the 90s, China began to implement a system of unpaid blood donation. INTCO has developed colloidal gold rapid diagnostic reagents in a timely manner, and obtained the production number of "hepatitis B surface antigen whole blood colloidal gold test strip" for the first time in 1999. The product is used in a large area of blood stations and street blood collection points, which not only ensures blood safety, reduces the blood scrap rate, but also greatly reduces the blood collection cost of the blood bank system.
In addition to paying attention to product quality, INTCO New Venture attaches more importance to product development and innovation, and has launched a number of patented products, such as the launch of the national exclusive patent gold standard HBSAG-TP joint inspection product in 2005In 2012, the exclusive patented "solid phase chromatography blood group card" was launched, which has become a star product of blood group detection in medical institutions with its technological innovation.
After more than 30 years of development, INTCO has continuously expanded its product line, and now has technology platforms such as enzyme immunization, POCT, biochemistry, chemiluminescence and molecular diagnosis, providing hundreds of millions of diagnostic products for primary medical institutions around the world, assisting in solving the problem of difficult primary medical examination and testing, and becoming a well-known in vitro diagnostic reagent manufacturer in China.
"One Health", "Health for All" and "Healthy China" are not just slogans, but must be put into action. INTCO will always adhere to the research and development and production of high-quality diagnostic reagents, and do its best to make products cover every place and every person, assist in early detection and early detection of diseases, and achieve global health goals as soon as possible.